Immunoprecise Antibodies Ltd Share Price Toronto S.E.
Equities
TQY
CA87588T2020
Pharmaceuticals
Sales 2024 * | 24.59M 18.03M 1.41B | Sales 2025 * | 29.82M 21.87M 1.71B | Capitalization | 39.08M 28.66M 2.24B |
---|---|---|---|---|---|
Net income 2024 * | -12M -8.8M -688M | Net income 2025 * | -9M -6.6M -516M | EV / Sales 2024 * | 1.59 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 1.31 x |
P/E ratio 2024 * |
-3.11
x | P/E ratio 2025 * |
-4.21
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.41% |
Latest transcript on Immunoprecise Antibodies Ltd
Managers | Title | Age | Since |
---|---|---|---|
Jennifer Bath
CEO | Chief Executive Officer | - | 20/02/18 |
Kristin Taylor
DFI | Director of Finance/CFO | - | 28/09/23 |
Ilse Roodink
CTO | Chief Tech/Sci/R&D Officer | - | 30/06/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mitchell Levine
CHM | Chairman | - | - |
Chris Buyse
BRD | Director/Board Member | 59 | 04/09/23 |
Jennifer Bath
CEO | Chief Executive Officer | - | 20/02/18 |
1st Jan change | Capi. | |
---|---|---|
-1.85% | 89.87B | |
-1.05% | 37.57B | |
-11.20% | 32.75B | |
+61.85% | 26.47B | |
-20.75% | 14.25B | |
-6.35% | 12.99B | |
-11.42% | 11.93B | |
-47.67% | 10.84B | |
+5.99% | 9.11B |